Phospholipid vesicles encapsulated bacteriophage: A novel approach to enhance phage biodistribution

Singla, Sumit; Harjai, Kusum; Raza, Kaisar; Wadhwa, Sheetu; Katare, Om Prakash; Chhibber, Sanjay

doi:10.1016/j.jviromet.2016.07.002

Cited by 47 publications

(26 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Encapsulated phage were present at higher peak levels and concentrations were maintained longer, declining after 12 hours for encapsulated phage compared to 6 hours for free phage. Phage remained detectable for up to 4 days in blood, 6 days in the liver, lungs and kidney, and up to 14 days in the spleen following a single intraperitoneal injection, compared to undetectable levels after 48 hours in all 4 organs when using free phage (aqueous suspension) [36]. The maintenance of maximal concentration and length of persistence of phage in the circulation observed in this study, suggests that systemic treatment may be possible using such approaches.…”

Section: Encapsulationmentioning

confidence: 53%

Recent Advances in Therapeutic Delivery Systems of Bacteriophage and Bacteriophage-Encoded Endolysins

et al. 2017

View full text Add to dashboard Cite

Antibiotics have been the cornerstone of clinical management of bacterial infection since their discovery in the early 20th century. However, their widespread and often indiscriminate use has now led to reports of multidrug resistance becoming globally commonplace. Bacteriophage therapy has undergone a recent revival in battle against pathogenic bacteria, as the self-replicating and co-evolutionary features of these predatory virions offer several advantages over conventional therapeutic agents. In particular, the use of targeted bacteriophage therapy from specialized delivery platforms has shown particular promise owing to the control of delivery location, administration conditions and dosage of the therapeutic cargo. This review presents an overview of the recent formulations and applications of such delivery vehicles as an innovative and elegant tool for bacterial control.

show abstract

Section: Encapsulationmentioning

confidence: 53%

Recent Advances in Therapeutic Delivery Systems of Bacteriophage and Bacteriophage-Encoded Endolysins

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Evidence for enhanced therapeutic effects and longer persistence of phages encapsulated within lipid-based drug delivery systems has also been provided by the findings of Singla et al (18). Moreover, it has been found that such encapsulated phages are well protected (up to 100%) from phage-neutralizing antibodies, which further increases their in vivo retention time within the body (13). Also, workers in the past (19,20) have shown that the use of such a delivery system improves the pharmacokinetics and biodistribution of the associated drug.…”

Section: Discussionmentioning

confidence: 87%

“…Our laboratory has reported the successful entrapment of phages within a suitable lipid-based delivery system, i.e., liposomes that are biocompatible and help to maintain the phage titer within the in vivo system (13). In the present study, the focus was on a different drug delivery system, i.e., transfersomes, which are most apt for the transdermal delivery of antimicrobial agents, especially in cases of skin and soft tissue infections.…”

Section: Discussionmentioning

confidence: 99%

Transfersomal Phage Cocktail Is an Effective Treatment against Methicillin-Resistant Staphylococcus aureus-Mediated Skin and Soft Tissue Infections

Chhibber

Shukla

Kaur

2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The emergence of drug resistance has rekindled interest in phage therapy as an alternative treatment option; its potency, safety, and proven efficacy are worth noting. However, phage therapy still suffers from issues of poor stability, narrow spectra, and poor pharmacokinetic profiles. Therefore, it is essential to look into the use of drug delivery systems for efficient delivery of lytic phages The present study evaluated the use of nanostructured lipid-based carriers, i.e., transfersomes, as transdermal delivery systems for encapsulating a methicillin-resistant (MRSA) phage cocktail. Furthermore, the therapeutic potential of the encapsulated phage cocktail in resolving experimental soft tissue infections in rats was studied. Results from stability and phage titer experiments indicated that the transfersome-entrapped phage cocktail showed better persistence and stability than did free phages. Rats treated with the transfersome-entrapped phage cocktail resolved the experimental thigh infections within a period of 7 days, unlike the 20-day period required for untreated animals. The findings of the present study support the use of transfersomes as delivery agents to enhance the stability and persistence of the encapsulated phages. In addition, this study highlights the advantages offered by transfersome-encapsulated phages in providing better therapeutic options than free phages for treating skin and soft tissue infections. The transfersome-entrapped phage cocktail was able to protect all test animals (with no deaths) even when administered with a delay of 12 h postinfection, unlike free phages, thus making this treatment option more suitable for clinical settings.

show abstract

“…In Singla et al [40], different approaches of incorporation of Klebsiella pneumoniae phage particles into liposomes as well as biodistribution of liposome-entrapped phages in various organs of BALB/c mice were evaluated. It turned out that liposome-entrapped phages were a few times more stable in blood and organs than free phages.…”

Section: Phage Therapy Nowmentioning

confidence: 99%

Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages

et al. 2016

View full text Add to dashboard Cite

The therapeutic use of bacteriophages has seen a renewal of interest blossom in the last few years. This reversion is due to increased difficulties in the treatment of antibiotic-resistant strains of bacteria. Bacterial resistance to antibiotics, a serious problem in contemporary medicine, does not implicate resistance to phage lysis mechanisms. Lytic bacteriophages are able to kill antibiotic-resistant bacteria at the end of the phage infection cycle. Thus, the development of phage therapy is potentially a way to improve the treatment of bacterial infections. However, there are antibacterial phage therapy difficulties specified by broadening the knowledge of the phage nature and influence on the host. It has been shown during experiments that both innate and adaptive immunity are involved in the clearance of phages from the body. Immunological reactions against phages are related to the route of administration and may vary depending on the type of bacterial viruses. For that reason, it is very important to test the immunological response of every single phage, particularly if intravenous therapy is being considered. The lack of these data in previous years was one of the reasons for phage therapy abandonment despite its century-long study. Promising results of recent research led us to look forward to a phage therapy that can be applied on a larger scale and subsequently put it into practice.

show abstract

Phospholipid vesicles encapsulated bacteriophage: A novel approach to enhance phage biodistribution

Cited by 47 publications

References 16 publications

Recent Advances in Therapeutic Delivery Systems of Bacteriophage and Bacteriophage-Encoded Endolysins

Recent Advances in Therapeutic Delivery Systems of Bacteriophage and Bacteriophage-Encoded Endolysins

Transfersomal Phage Cocktail Is an Effective Treatment against Methicillin-Resistant Staphylococcus aureus-Mediated Skin and Soft Tissue Infections

Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages

Contact Info

Product

Resources

About